Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) | Chorismate synthase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | 0.0098 | 0.1321 | 0.7543 |
Entamoeba histolytica | hypothetical protein | 0.0033 | 0.0245 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0124 | 0.1752 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0098 | 0.1321 | 0.7543 |
Mycobacterium ulcerans | chorismate synthase | 0.0216 | 0.3256 | 0.5 |
Chlamydia trachomatis | chorismate synthase | 0.0216 | 0.3256 | 0.5 |
Plasmodium falciparum | chorismate synthase | 0.0216 | 0.3256 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0033 | 0.0245 | 0.5 |
Plasmodium vivax | chorismate synthase | 0.0216 | 0.3256 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0033 | 0.0245 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0033 | 0.0245 | 0.0245 |
Mycobacterium tuberculosis | Probable chorismate synthase AroF (5-enolpyruvylshikimate-3-phosphate phospholyase) | 0.0106 | 0.1454 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0033 | 0.0245 | 1 |
Mycobacterium leprae | Chorismate synthase AroF (5-enolpyruvylshikimate-3-phosphate phospholyase). | 0.0106 | 0.1454 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0033 | 0.0245 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0033 | 0.0245 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0098 | 0.1321 | 0.7543 |
Onchocerca volvulus | 0.0124 | 0.1752 | 1 | |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0033 | 0.0245 | 1 |
Brugia malayi | hypothetical protein | 0.0124 | 0.1752 | 1 |
Brugia malayi | hypothetical protein | 0.0033 | 0.0245 | 0.1399 |
Toxoplasma gondii | chorismate synthase, putative | 0.0216 | 0.3256 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.